b03ebc32.a177.44c7.8b02.fcd6560712f2
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.250
- BILE_ACID_METABOLISM+0.220
- NOTCH_SIGNALING+0.200
- HEDGEHOG_SIGNALING+0.180
- XENOBIOTIC_METABOLISM+0.050
- SPERMATOGENESIS+0.030
- MYOGENESIS+0.010
- PEROXISOME-0.020
- UV_RESPONSE_DN-0.020
- FATTY_ACID_METABOLISM-0.050
Top 10 suppressed
- MYC_TARGETS_V1-0.580
- MYC_TARGETS_V2-0.570
- G2M_CHECKPOINT-0.510
- MTORC1_SIGNALING-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.500
- E2F_TARGETS-0.490
- OXIDATIVE_PHOSPHORYLATION-0.450
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02950 | — | cohortA1 | 0.969 |
| 2 | TCGA-55-A4DG-01A-11R-A24H-07 | — | cohortA1 | 0.941 |
| 3 | SRR2016932 | — | — | 0.925 |
| 4 | BS_0Y66ZBWE | low-grade glioma | — | 0.924 |
| 5 | BS_C80S5N37 | EPN | EPN Tumor | 0.921 |
| 6 | SRR6013517 | — | cohortA1 | 0.919 |
| 7 | TCGA-G2-A3IE-01A-11R-A20F-07 | — | — | 0.910 |
| 8 | SRR1443824 | GTEX | — | 0.907 |
| 9 | BS_0T17SY47 | low-grade glioma | — | 0.906 |
| 10 | BS_V7BJM89K | low-grade glioma | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |